MXPA05009386A - Compuestos arilvinilazacicloalcano y metodos de preparacion y uso de los mismos. - Google Patents

Compuestos arilvinilazacicloalcano y metodos de preparacion y uso de los mismos.

Info

Publication number
MXPA05009386A
MXPA05009386A MXPA05009386A MXPA05009386A MXPA05009386A MX PA05009386 A MXPA05009386 A MX PA05009386A MX PA05009386 A MXPA05009386 A MX PA05009386A MX PA05009386 A MXPA05009386 A MX PA05009386A MX PA05009386 A MXPA05009386 A MX PA05009386A
Authority
MX
Mexico
Prior art keywords
disorders
compounds
disease
central nervous
nachrs
Prior art date
Application number
MXPA05009386A
Other languages
English (en)
Inventor
Gary Maurice Dull
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of MXPA05009386A publication Critical patent/MXPA05009386A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Se describen los compuestos vinilazacicloalcano novedosos de formula (I); los compuestos son ligandos de diversos nAChRs; los compuestos y sus sales farmaceuticamente aceptables se pueden utilizar para preparar composiciones farmaceuticas y/o medicamentos que se pretenden para prevenir o tratar trastornos asociados con la disfuncion sobre los nAChRs, especialmente en el sistema nervioso central o el sistema gastrointestinal; los ejemplos de tipos de trastornos que se pueden tratar incluyen trastornos neurodegenerativos, incluyendo trastornos del sistema nervioso central tales como enfermedad de Alzheimer, trastornos cognitivos, trastornos motores tales como enfermedad de Parkinson, adiccion a drogas, trastornos conductuales y trastornos inflamatorios en el sistema gastrointestinal; los compuestos tambien pueden servir como analgesicos en el tratamiento de dolor agudo, cronico o recurrente.
MXPA05009386A 2003-03-05 2004-03-04 Compuestos arilvinilazacicloalcano y metodos de preparacion y uso de los mismos. MXPA05009386A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/379,868 US7098331B2 (en) 2003-03-05 2003-03-05 Arylvinylazacycloalkane compounds and methods of preparation and use thereof
PCT/US2004/006530 WO2004078752A1 (en) 2003-03-05 2004-03-04 Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
MXPA05009386A true MXPA05009386A (es) 2005-11-04

Family

ID=32926772

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009386A MXPA05009386A (es) 2003-03-05 2004-03-04 Compuestos arilvinilazacicloalcano y metodos de preparacion y uso de los mismos.

Country Status (32)

Country Link
US (8) US7098331B2 (es)
EP (3) EP1601670B1 (es)
JP (3) JP4663627B2 (es)
KR (4) KR20120014236A (es)
CN (3) CN101550132B (es)
AR (3) AR043469A1 (es)
AT (3) ATE517893T1 (es)
AU (3) AU2004217903B2 (es)
BR (1) BRPI0409576A (es)
CA (1) CA2516514C (es)
CL (1) CL2004000452A1 (es)
CY (2) CY1110391T1 (es)
DE (2) DE602004031165D1 (es)
DK (2) DK1601670T3 (es)
EA (3) EA019240B1 (es)
ES (3) ES2389106T3 (es)
GT (1) GT200400033A (es)
HK (3) HK1084949A1 (es)
IL (3) IL170155A (es)
JO (1) JO2488B1 (es)
MX (1) MXPA05009386A (es)
NO (3) NO331920B1 (es)
NZ (1) NZ541795A (es)
PA (1) PA8597201A1 (es)
PE (1) PE20040930A1 (es)
PL (5) PL1601670T3 (es)
PT (2) PT1601670E (es)
SI (2) SI2085395T1 (es)
TW (3) TWI377204B (es)
UY (1) UY28218A1 (es)
WO (1) WO2004078752A1 (es)
ZA (1) ZA200506790B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
FR2896800B1 (fr) * 2006-01-30 2008-04-11 Servier Lab Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
WO2009140201A1 (en) * 2008-05-12 2009-11-19 Targacept, Inc. Methods for preventing the development of retinopathy by the oral administration of nnr ligands
TW201024283A (en) * 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
UA107336C2 (ru) * 2008-12-01 2014-12-25 Таргасепт, Інк. Синтез и солевые формы (r)-5-((e)-2-пирролидин-3-илвинил) пиримидина
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
WO2010147938A2 (en) * 2009-06-17 2010-12-23 Targacept, Inc. Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
BR112012013765A2 (pt) 2009-12-07 2016-04-26 Targacept Inc 3,6-diazabiciclo[3.1.1] heptanos como ligantes de receptor nicotínico neuronal de acetilcolina
AU2011224697A1 (en) * 2010-03-11 2012-10-04 Targacept, Inc. Arylvinylazacycloalkane compounds for constipation
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20140081714A1 (en) * 2012-09-19 2014-03-20 Salesforce.Com, Inc. Systems and methods of rewarding users in an on-demand system
US20140278929A1 (en) * 2013-03-15 2014-09-18 Yahoo! Inc. System and method identifying opportunities for advertising entities based on user goal achievement
DK3439661T3 (da) 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser
KR101848601B1 (ko) * 2016-07-27 2018-04-12 송기봉 일회용 위생 티슈
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
TW202206078A (zh) 2020-04-28 2022-02-16 美商奧伊斯特普安生物製藥公司 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) * 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6437138B1 (en) * 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
DE69826883T2 (de) 1997-10-27 2005-02-03 Neurosearch A/S Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren
WO2000075110A1 (en) 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
MXPA02002115A (es) 1999-09-14 2002-10-31 Abbott Lab Compuestos de eter 3-pirrolidiniloxi-3'-piridilico, utiles para controlar la transmision sinaptica quimica. .
WO2001032264A1 (en) 1999-11-01 2001-05-10 Targacept, Inc. Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors
US6624167B1 (en) * 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
AU2002322562A1 (en) 2001-07-19 2003-03-03 Medical College Of Georgia Research Institute Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Also Published As

Publication number Publication date
PL394600A1 (pl) 2011-07-18
CN101255155A (zh) 2008-09-03
KR20090021228A (ko) 2009-02-27
US20040176348A1 (en) 2004-09-09
TWI377204B (en) 2012-11-21
EP2085395A1 (en) 2009-08-05
NO20054120D0 (no) 2005-09-05
HK1084949A1 (en) 2006-08-11
ES2309507T3 (es) 2008-12-16
SI2085395T1 (sl) 2011-05-31
HK1116800A1 (en) 2009-01-02
JP2010001296A (ja) 2010-01-07
EP1601670A1 (en) 2005-12-07
US20080293778A1 (en) 2008-11-27
US7714001B2 (en) 2010-05-11
AR043469A1 (es) 2005-07-27
DK2085395T3 (da) 2011-04-18
US20060094732A1 (en) 2006-05-04
IL170155A (en) 2013-08-29
NO331920B1 (no) 2012-04-30
AU2008258188A1 (en) 2009-01-15
NO20092231L (no) 2005-10-03
ES2385941T3 (es) 2012-08-03
CA2516514A1 (en) 2004-09-16
EP1947100A1 (en) 2008-07-23
US20110152293A1 (en) 2011-06-23
PA8597201A1 (es) 2004-09-28
CN1756754A (zh) 2006-04-05
PT1601670E (pt) 2008-07-11
EP2085395B1 (en) 2011-01-19
NO20054120L (no) 2005-10-03
US20100267776A1 (en) 2010-10-21
US7098331B2 (en) 2006-08-29
PL2085395T3 (pl) 2011-05-31
EA200501425A1 (ru) 2006-02-24
NZ541795A (en) 2008-03-28
IL197889A (en) 2013-03-24
SI1601670T1 (sl) 2008-10-31
JP2006519868A (ja) 2006-08-31
CN100526308C (zh) 2009-08-12
KR20120014236A (ko) 2012-02-16
JP5537085B2 (ja) 2014-07-02
EA010870B1 (ru) 2008-12-30
KR20090021227A (ko) 2009-02-27
HK1130254A1 (en) 2009-12-24
EA014714B1 (ru) 2011-02-28
CY1111615T1 (el) 2015-10-07
US8063068B2 (en) 2011-11-22
ATE517893T1 (de) 2011-08-15
DK1601670T3 (da) 2008-08-25
AR070569A2 (es) 2010-04-21
NO332293B1 (no) 2012-08-20
JO2488B1 (en) 2009-10-05
PL215059B1 (pl) 2013-10-31
KR100953150B1 (ko) 2010-04-19
AU2008258187B2 (en) 2010-08-05
PL216979B1 (pl) 2014-06-30
GT200400033A (es) 2005-05-29
DE602004031165D1 (de) 2011-03-03
UY28218A1 (es) 2005-06-30
ES2389106T3 (es) 2012-10-23
EP1601670B1 (en) 2008-05-07
EA019240B1 (ru) 2014-02-28
US20140107164A1 (en) 2014-04-17
BRPI0409576A (pt) 2006-04-18
ZA200506790B (en) 2006-05-31
CN101550132B (zh) 2012-03-28
US20100010042A1 (en) 2010-01-14
TWI339662B (en) 2011-04-01
AU2004217903B2 (en) 2010-03-04
JP5537084B2 (ja) 2014-07-02
DE602004013553D1 (de) 2008-06-19
KR20060006006A (ko) 2006-01-18
PT2085395E (pt) 2011-04-20
AU2004217903A1 (en) 2004-09-16
EA200900706A1 (ru) 2009-10-30
US20150164894A1 (en) 2015-06-18
ATE496046T1 (de) 2011-02-15
PL1601670T3 (pl) 2008-10-31
NO20091888L (no) 2005-10-03
US8067443B2 (en) 2011-11-29
KR101185541B1 (ko) 2012-09-24
JP2009292825A (ja) 2009-12-17
CY1110391T1 (el) 2015-04-29
ATE394394T1 (de) 2008-05-15
AU2008258187A1 (en) 2009-01-15
PE20040930A1 (es) 2005-02-18
TW200927746A (en) 2009-07-01
EA200801764A1 (ru) 2008-12-30
KR101018083B1 (ko) 2011-03-02
IL197890A (en) 2013-11-28
CN101550132A (zh) 2009-10-07
AR070570A2 (es) 2010-04-21
PL394604A1 (pl) 2011-07-18
US8633222B2 (en) 2014-01-21
EP1947100B1 (en) 2011-07-27
CL2004000452A1 (es) 2005-05-20
JP4663627B2 (ja) 2011-04-06
AU2008258188B2 (en) 2011-02-24
PL378415A1 (pl) 2006-04-03
TW200927745A (en) 2009-07-01
TW200505909A (en) 2005-02-16
CA2516514C (en) 2012-02-07
WO2004078752A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
IL197890A (en) Arylvinylchloroalkylan compounds and their preparation methods and uses
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2004110388A3 (en) Sigma ligands for neuronal regeneration and functional recovery
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2007025286A3 (en) Therapy procedure for drug delivery for trigeminal pain
TW200635903A (en) Therapeutic agents
TW200633986A (en) Therapeutic agents
PL1678172T3 (pl) Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego
TW200728300A (en) Therapeutic agents
DE60320579D1 (de) Mucuna pruriens und extrakte daraus zur behandlung von neurologischen erkrankungen
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
WO2005094497A3 (en) Systemic delivery of therapeutics to central nervous system
TW200510331A (en) Heteroaryl-substituted imidazole derivatives
TW200501958A (en) A therapeutic agent for treating a behavioral disorder

Legal Events

Date Code Title Description
FG Grant or registration